A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

@article{Cao2020ATO,
  title={A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19},
  author={Bin Cao and Ye-ming Wang and Danning Wen and Wen Liu and Jingli Wang and Guohui Fan and Lianguo Ruan and Bin Song and Yanping Cai and Ming Wei and Xingwang Li and Jia'an Xia and Nanshan Chen and Jie Xiang and Ting Yu and Tao Bai and Xuelei Xie and Li Zhang and Caihong Li and Ye Yuan and Hua Chen and Huadong Li and Hanping Huang and Shengjin Tu and Fengyun Gong and Ying Liu and Yuan Wei and Chongya Dong and Fei Zhou and Xiaoying Gu and Jiuyang Xu and Zhibo Liu and Yan-lin Zhang and Hui Li and Lianhan Shang and Ke Wang and Kunxia Li and Xia Zhou and Xuan Dong and Zhaohui Qu and Sixia Lu and Xujuan Hu and Shunan Ruan and Shanshan Luo and Jing Wu and Lu Peng and Fang Cheng and Li-juan Pan and Jun Zou and Chunmin Jia and Juan Wang and Xia Liu and Shuzhen Wang and Xudong Wu and Qing Ge and Jing He and Haiyan Zhan and Fang Qiu and Li Guo and Chaolin Huang and Thomas F. Jaki and Frederick G. Hayden and Peter W. Horby and Dingyu Zhang and Chen Wang},
  journal={The New England Journal of Medicine},
  year={2020}
}
Abstract Background No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2. Methods We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (Sao2) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen (Pao2) to the fraction of inspired oxygen (Fio2) of less… 

Paper Mentions

Interventional Clinical Trial
Blinded, multicenter, placebo-controlled, randomized clinical trial evaluating lopinavir/ritonavir vs placebo in early outpatient treatment of adults with COVID-19  
ConditionsCOVID-19
InterventionDrug, Other
Interventional Clinical Trial
The Açaí trial will be testing if the açaí berry extract, a safe natural product with anti-inflammatory properties, can be used as a treatment option in adult patients with COVID… 
ConditionsCOVID
InterventionDietary Supplement, Other
Interventional Clinical Trial
A series of microbiota were correlated inversely with the disease severity and virus load. Gut microbiota could play a role in modulating host immune response and potentially influence… 
ConditionsCoronavirus
InterventionOther
Interventional Clinical Trial
CCAP is an investigator-initiated multicentre, randomized, double blinded, placebo-controlled trial, which aims to assess the safety and efficacy of treatment with convalescent plasma… 
ConditionsCorona Virus Infection, COVID, Viral Pneumonia
InterventionBiological, Other
Remdesivir for the Treatment of Covid-19 — Final Report
TLDR
The data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.
Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial
TLDR
In patients with mild Covid-19, no benefit was observed with HCQ beyond the usual care and the time to complete resolution of symptoms was shortened.
Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
TLDR
Adding Favipiravir to the treatment protocol did not reduce the number of ICU admissions or intubations or In-hospital mortality compared to Lopinavir/Ritonavir regimen, and it also did not shorten time to clinical recovery and length of hospital stay.
Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial
TLDR
Although the duration of hospitalization in the lopinavir/ritonavir + atorvastatin group was significantly reduced compared to the control group, there was no significant difference in the invasive mechanical ventilation reception and the need for interferon and immunoglobulin.
Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial
TLDR
LPV/r or arbidol monotherapy present little benefit for improving the clinical outcome of patients hospitalized with mild/moderate COVID-19 over supportive care, and no apparent adverse event occurred in the control group.
Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
TLDR
There was a numerical reduction in mortality rate, less intensive care unit stay and less complications in the lopinavir-ritonavir group and some suggestions for future clinical trials are pointed out.
Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients
TLDR
No statistically significant differences were observed in outcome parameters in patients treated with HCQ or LPV/RTV but patients in the LPV-RTV group showed a numerically lower hospital mortality rate.
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
TLDR
In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits, however, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies.
A retrospective analysis of clinical efficacy of ribavirin in adults hospitalized with severe COVID-19
TLDR
In hospitalized adult patients with severe COVID-19, no significant benefit was observed with ribavirin treatment and there were no significant differences between-group in SARS-CoV-2 nucleic acid negative conversion, mortality, survival time, and the length of hospital stay.
Hydroxychloroquine versus Azithromycin for Hospitalized Patients with COVID-19. Results of a Randomized, Active Comparator Trial
TLDR
The results are consistent with conclusions from other trials that hydroxychloroquine cannot be recommended for inpatients with COVID-19; azithromycin may merit additional investigation.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
TLDR
The apparent favourable clinical response with lopinavir/ritonavir and ribavirin supports further randomised placebo controlled trials in patients with SARS and shows that age, hepatitis B carrier status, and lack of treatment with this antiviral combination were independent predictors of an adverse outcome.
Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial
TLDR
The aim of this study is to investigate the efficacy of treatment with a combination of lopinavir/ritonavir and recombinant IFN-β1b provided with standard supportive care in patients with laboratory-confirmed MERS requiring hospital admission.
Combination Therapy with Lopinavir/Ritonavir, Ribavirin and Interferon-α for Middle East Respiratory Syndrome
TLDR
This is a case report of use of lopinavir/ritonavir-based combination antiviral therapy for a patient with MERS-CoV infection.
Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
TLDR
3 repurposed drugs with potent in vitro anti-MERS-CoV activity are assessed in common marmosets with severe disease resembling MERS in humans and lopinavir/ritonavir and interferon-β1b alone or in combination should be evaluated in clinical trials.
Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection.
TLDR
Favipiravir and oseltamivir combination therapy may accelerate clinical recovery compared to oselTAMivir monotherapy in severe influenza, and this strategy should be formally evaluated in a randomized controlled trial.
Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09.
  • J. Louie, Samuel Yang, +5 authors T. Uyeki
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2012
TLDR
NAI treatment of critically ill pH1N1 patients improves survival, while earlier treatment conveyed the most benefit, patients who started treatment up to 5 days after symptom onset also were more likely to survive.
Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.
TLDR
The addition of lopinavir/ritonavir to a standard treatment protocol as an initial treatment for severe acute respiratory syndrome appeared to be associated with improved clinical outcome.
Early Oseltamivir After Hospital Admission Is Associated With Shortened Hospitalization: A 5-Year Analysis of Oseltamivir Timing and Clinical Outcomes.
TLDR
Over multiple influenza seasons, early NAI therapy was associated with shorter LOS in patients admitted with influenza, suggesting that efforts should focus on facilitating earlier therapy in patients with suspected influenza.
Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays.
TLDR
Compared with different IFN products, IFN-β, MPA or a combination of the two may be beneficial in the treatment of MERS-CoV or as a post-exposure intervention in high-risk patients with known exposures to MSPV.
Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.
TLDR
There was an increase in the mortality hazard rate with each day's delay in initiation of treatment up to day 5 as compared with treatment initiated within 2 days of symptom onset, and early treatment versus no treatment was also associated with a reduction in mortality risk.
...
1
2
3
4
...